Helix BioPharma Corp. (TSX: HBP; OTC: HBPCF; FRANKFURT: HBP0), a clinical-stage oncology company developing therapies for difficult-to-treat cancers, on Thursday reported a net loss and total comprehensive loss of $3,354,000 for the fiscal year ended July 31, 2026, or $0.04 per common share, an improvement from a loss of $5,205,000, or $0.09 per share, in the prior year, according to the company's earnings release distributed via NEWMEDIAWIRE.
The narrower loss stemmed largely from a 54% reduction in research and development spending, which fell to $1,620,000 from $3,558,000, reflecting the wind-down of prior clinical activities, including the LDOS006 study in metastatic pancreatic adenocarcinoma, and the deferral of external service provider engagements pending successful fundraising. Operating, general and administration expenses rose 10% to $2,019,000, driven by higher stock-based compensation tied to a May 2026 option grant and increased salaries from full-year officer appointments. Detailed expense breakdowns were provided in Table 1 and Table 2.
The more pressing issue for investors is liquidity. As of July 31, 2026, Helix reported a working capital deficiency of $4,181,000, shareholders' equity of $14,208,000, an accumulated deficit of $219,230,000, and cash reserves of just $804,000, which the company said are insufficient to meet anticipated working capital and capital expenditure requirements over the next twelve months or to complete current research and development initiatives. Management stated that securing additional funds primarily through equity arrangements is of the utmost importance and is evaluating financing alternatives. The company's strategy contemplates bridge financing to support near-term objectives and prepare for a subsequent, larger financing intended to fund the next stages of clinical development, including the planned Phase Ib/randomized Phase II study of L-DOS47 in combination with pembrolizumab as first-line therapy in non-small cell lung cancer.
Why this matters: Helix's cash position and going-concern language signal that without a successful capital raise, the company may be unable to advance its pipeline, potentially delaying or halting development of its lead candidate. The closing price of the common shares on the TSX was $0.92 on October 8, 2026, below the $1.42 conversion price of $3,673,000 in unsecured convertible debentures issued in May 2026, which bear 25% simple interest and mature July 27, 2027. A previously announced $33,370,000 equity financing with Quantum Global Ventures AG did not close after the subscriber declared bankruptcy, and a $1,667,000 private placement closed in August 2025 at $0.75 per share. The company also signed a term sheet with Alumni Capital Limited for a potential financing transaction, though terms were not disclosed.
Operationally, Helix strengthened its leadership with the August 2026 appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer, bringing over 30 years of oncology drug development experience, and the June 2026 appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. In September 2026, the board was reconstituted with Karen Krumeich as Chair, alongside Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt, leaving six directors, five of whom are independent. The company also extended its Research and Exclusive Option Agreement with metaShape Pharma AG covering LEUMUNA for adipose tissue-related and metabolic diseases through December 31, 2028, preserving strategic optionality while maintaining focus on oncology.
Helix's common shares trade on the TSX under HBP, on the OTC Pink Market under HBPCF, and on the Frankfurt Stock Exchange under HBP0. The company's financial statements, management's discussion and analysis, and annual information form are available under its profile on SEDAR+ and on its website at www.helixbiopharma.com.
The company's ability to continue as a going concern and to advance its pipeline, including L-DOS47, LEUMUNA, and GEMCEDA, remains contingent on securing sufficient financing and meeting applicable regulatory and development requirements, making the next several months critical for stakeholders.
